SCHEMBL4759633

SCHEMBL4759633

CCOC(=O)C1(C(=O)OCC)CC(C)=C(C)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.43
ATM Q13315 1/20 0.41
ALDH1A1 P00352 2/20 0.40
ALOX15 P16050 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 1/20 0.39
LMNA P02545 2/20 0.39
HSD17B10 Q99714 1/20 0.39
BRD4 O60885 1/20 0.38
OPRM1 P35372 6/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
SOAT1 P35610 1/20 0.37
OPRD1 P41143 3/20 0.37
OPRK1 P41145 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4740325 0.90 POLB (0.40) POLBATMALDH1A1ALOX15MEN1
SCHEMBL3147434 0.84 POLB (0.46) POLBATMALDH1A1ALOX15MEN1
SCHEMBL8653250 0.83 POLB (0.41) POLBATMALDH1A1ALOX15MEN1
SCHEMBL3133383 0.83 ATM (0.46) POLBATMALDH1A1ALOX15MEN1
SCHEMBL8995766 0.81 POLB (0.43) POLBATMALDH1A1ALOX15MEN1
SCHEMBL21192369 0.79 MEN1 (0.33) POLBATMMEN1KMT2AKDM4E
SCHEMBL15070910 0.78 POLB (0.41) POLBATMALDH1A1ALOX15MEN1
SCHEMBL18134201 0.78 ALDH1A1 (0.46) POLBATMALDH1A1ALOX15MEN1
SCHEMBL69496 0.78 ALDH1A1 (0.46) POLBATMALDH1A1ALOX15MEN1
SCHEMBL10427679 0.78 BRD4 (0.43) POLBMEN1KMT2ABRD4OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220219155-A1 Compositions And Methods For Visible-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2022-07-14 US disclosed
US-20220161245-A1 Compositions And Methods For Infrared-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2022-05-26 US disclosed
US-20210237045-A1 USE OF N-CHELATING RUTHENIUM COMPLEXES IN THE METATHESIS REACTION APEIRON SYNTHESIS S.A. (PL) 2021-08-05 US disclosed
EP-3068768-B1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME (US) 2019-07-31 EP disclosed
EP-3068768-B1 ANTIDIABETIC TRICYCLIC COMPOUNDS MERCK SHARP & DOHME (US) 2019-07-31 EP disclosed
US-20180065914-A1 RUTHENIUM POLYMERISATION CATALYSTS UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) 2018-03-08 US disclosed
US-9815765-B2 Ruthenium polymerisation catalysts UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS (GB) 2017-11-14 US disclosed
US-9776178-B2 Ruthenium complexes comprising an asymmetrical unsaturated N-heterocyclic diaminocarbene ECOLE NATIONALE SUPERIEURE DE CHIMIE DE RENNES (FR) 2017-10-03 US disclosed
US-20170145152-A1 GROUP 8 TRANSITION METAL CATALYSTS AND METHOD FOR MAKING SAME AND PROCESS FOR USE OF SAME IN METATHESIS REACTION GUANG MING INNOVATION COMPANY (WUHAN) (CN) 2017-05-25 US disclosed
EP-3068768-A1 ANTIDIABETIC TRICYCLIC COMPOUNDS Merck Sharp & Dohme Corp. (US) 2016-09-21 EP disclosed
US-8361922-B2 Organometallic ruthenium complexes and related methods for the preparation of tetra-substituted and other hindered olefins MATERIA, INC. (US) 2013-01-29 US disclosed
WO-2012116695-A1 MOLYBDENUM AND TUNGSTEN METAL COMPLEXES AND USE THEREOF AS PRECATALYSTS FOR OLEFIN METATHESIS STUDIENGESELLSCHAFT KOHLE MBH (DE) 2012-09-07 WO disclosed
US-20120123133-A1 ORGANOMETALLIC RUTHENIUM COMPLEXES AND RELATED METHODS FOR THE PREPARATION OF TETRA-SUBSTITUTED AND OTHER HINDERED OLEFINS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2012-05-17 US disclosed
US-8008224-B2 Organometallic ruthenium complexes and related methods for the preparation of tetra-substituted and other hindered olefins MATERIA, INC. (US) 2011-08-30 US disclosed
US-8008224-B2 Organometallic ruthenium complexes and related methods for the preparation of tetra-substituted and other hindered olefins MATERIA, INC. (US) 2011-08-30 US disclosed
US-20070282148-A1 Organometallic ruthenium complexes and related methods for the preparation of tetra-substituted and other hindered olefins CALIFORNIA INSTITUTE OF TECHNOLOGY 2007-12-06 US disclosed
US-20070282148-A1 Organometallic ruthenium complexes and related methods for the preparation of tetra-substituted and other hindered olefins CALIFORNIA INSTITUTE OF TECHNOLOGY 2007-12-06 US disclosed
WO-2007075427-A1 ORGANOMETALLIC RUTHENIUM COMPLEXES AND RELATED METHODS FOR THE PREPARATION OF TETRA-SUBSTITUTED AND OTHER HINDERED OLEFINS MATERIA, INC. (US) 2007-07-05 WO disclosed
EP-1743899-A1 Metal complexes for use in metathesis, atom transfer radical reactions, addition polymerisation and vinylation reactions, methods and intermediates for making them Universiteit Gent (BE) 2007-01-17 EP disclosed
EP-1468004-B1 METAL COMPLEXES FOR USE IN METATHESIS UNIV GENT (BE) 2006-12-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120123133-A1 ORGANOMETALLIC RUTHENIUM COMPLEXES AND RELATED METHODS FOR THE PREPARATION OF TETRA-SUBSTITUTED AND OTHER HINDERED OLEFINS ORC3, OXER1, CBR3 POLB 2244/4885ATM 1880/4885ALDH1A1 2951/4885
US-20210237045-A1 USE OF N-CHELATING RUTHENIUM COMPLEXES IN THE METATHESIS REACTION CYC1, AP1M1, HNMT POLB 575/4885ATM 3706/4885ALDH1A1 1856/4885
US-20070282148-A1 Organometallic ruthenium complexes and related methods for the preparation of tetra-substituted and other hindered olefins ORC3, OXER1, CBR3 POLB 2244/4885ATM 1880/4885ALDH1A1 2951/4885
US-20170145152-A1 GROUP 8 TRANSITION METAL CATALYSTS AND METHOD FOR MAKING SAME AND PROCESS FOR USE OF SAME IN METATHESIS REACTION F8, COASY, FADS1 POLB 3132/4885ATM 3514/4885ALDH1A1 1858/4885
US-20220161245-A1 Compositions And Methods For Infrared-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis CYBB, CYBA, CYB5R3 POLB 322/4885ATM 491/4885ALDH1A1 714/4885
US-20180065914-A1 RUTHENIUM POLYMERISATION CATALYSTS RRP12, PCBP1, PARG POLB 309/4885ATM 1741/4885ALDH1A1 4132/4885
US-20220219155-A1 Compositions And Methods For Visible-Light-Controlled Ruthenium-Catalyzed Olefin Metathesis PPOX, CYBA, CYBB POLB 316/4885ATM 545/4885ALDH1A1 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.